首页|Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Where are we?
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Where are we?
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
维普
Peritoneal surface malignancies are generally associated with poor prognosis.In daily clinical routine,systemic chemotherapy is still considered the only reasonable therapy despite of encouraging results of cytoreductive surgery (CRS) along with intraperitoneal hyperthermic chemotherapy (HIPEC).The Achilles heel of CRS and HIPEC is appropriate patient selection and precise surgical technique preventing patients from excessive morbidity and mortality.Given these findings,new concepts of second look surgery for high risk patients allow detection of peritoneal spread ahead of clinical symptoms or presence of peritoneal masses reducing perioperative morbidity.In addition,personalized intraperitoneal chemotherapy might further improve outcome by appreciating individual tumor biology.These days,every physician should be aware of CRS and HIPEC for treatment of peritoneal surface malignancies.Since there is now sufficient data for the superiority of CRS and HIPEC to systemic chemotherapy in selected patients,our next goal should be providing this strategy with minimal morbidity and mortality even in the presence of higher tumor load.
Peritoneal carcinomatosisHyperthermic intraperitoneal chemotherapyCytoreductive surgery
Ingmar K(o)nigsrainer、Stefan Beckert
展开 >
Department of General,Visceral and Transplant Surgery, Tübingen University Hospital,D-72076 Tübingen, Germany
NETL
NSTL
万方数据
维普
